Skip to main content

Table 1 Baseline patient characteristics

From: Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study

  All Patients Pirfenidone Nintedanib P Value1
N = 1455 N = 799 N = 656
Age, mean (SD) 70.9 (9.5) 70.6 (9.4) 71.3 (9.7) 0.222
Age categories, years, n (%)     0.581
 40–44 1 (0.1) 1 (0.1) (0.0)  
 45–54 68 (4.7) 36 (4.5) 32 (4.9)  
 55–64 377 (25.9) 212 (26.5) 165 (25.2)  
 65–74 445 (30.6) 255 (31.9) 190 (29.0)  
 75–79 269 (18.5) 140 (17.5) 129 (19.7)  
 ≥ 80 295 (20.3) 155 (19.4) 140 (21.3)  
Female, n (%) 456 (31.3) 256 (32.0) 200 (30.5) 0.525
Region, n (%)     0.010
 Northeast 271 (18.6) 157 (19.6) 114 (17.4)  
 North Central 457 (31.4) 236 (29.5) 221 (33.7)  
 South 554 (38.1) 294 (36.8) 260 (39.6)  
 West 169 (11.6) 111 (13.9) 58 (8.8)  
 Unknown 4 (0.3) 1 (0.1) 3 (0.5)  
CCI, mean (SD) 2.1 (2.0) 2.1 (2.0) 2.1 (1.9) 0.512
   excluding COPD, mean (SD) 1.9 (2.0) 1.9 (2.0) 1.9 (1.9) 0.680
Proxies of disease severity, n (%)
 Presence of supplemental oxygen use 868 (59.7) 478 (59.8) 390 (59.5) 0.885
 Diagnosis of dyspnea 1131 (77.7) 621 (77.7) 510 (77.7) 0.992
 Prescription for ≥1 opioid(s) 557 (38.3) 306 (38.3) 251 (38.3) 0.989
Presence of comorbid conditions, n (%)
 Any cardiovascular disease 640 (44.0) 354 (44.3) 286 (43.6) 0.787
  Stroke 37 (2.5) 23 (2.9) 14 (2.1) 0.369
 COPD 692 (47.6) 359 (44.9) 333 (50.8) 0.027
  Emphysema 189 (13.0) 99 (12.4) 90 (13.7) 0.453
  Bronchitis 101 (6.9) 51 (6.4) 50 (7.6) 0.355
  Chronic bronchitis 156 (10.7) 73 (9.1) 83 (12.7) 0.031
  Chronic airway obstruction 562 (38.6) 289 (36.2) 273 (41.6) 0.034
 Cancer 269 (18.5) 154 (19.3) 115 (17.5) 0.394
  Lung cancer 31 (2.1) 21 (2.6) 10 (1.5) 0.147
 Recent pnemonia2 149 (10.2) 77 (9.6) 72 (11.0) 0.402
All-cause total costs, mean (SD) $31,933 ($54,125) $31,849 ($44,706) $32,035 ($63,781) 0.948
Visit to ILD center of excellence3, n (%) 110 (7.6) 57 (7.1) 53 (8.1) 0.497
  1. CCI Charlson Comorbidity Index, COPD chronic obstructive pulmonary disease, SD standard deviation
  2. 1Pirfenidone vs. nintedanib
  3. 2Pneumonia diagnosis in the 3 months immediately preceding the index date
  4. 3 Patient was treated at an Interstitial Lung Disease (ILD) Center of Excellence as identified by zip code of facility. Centers of excellence were defined as medical centers with specific expertise in the treatment of pulmonary fibrosis, as recognized by the Pulmonary Fibrosis Foundation